An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

NCT07293754 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumor

Interventions

DRUG: RPTR-1-201
DRUG: PD-1 / PD-L1 monoclonal antibody

Sponsor

Repertoire Immune Medicines